Concepedia

Kurt Lustig

KL

Statistics

Publications

5

Citations

165

H-Index

5

Active since

2004

Affiliations

Targeted Medical Pharma (United States)(Current)

Kineta (United States)

Target (United States)

Kurt Lustig is an author at Targeted Medical Pharma (United States) specializing in immunology, life sciences, and molecular virology.

Publications per year

2004–2023

5

Publications

5

AAV2/1-TNFR:Fc gene delivery prevents periodontal disease progression

Joni Augusto Cirelli, C H Park, K MacKool et al. · Gene Therapy · 2008 · 58 citations · Full text

, , +14

A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Shawn P. Iadonato, Yulia Ovechkina, Kurt Lustig et al. · Frontiers in Immunology · 2023 · 38 citations · Full text

, , +17

Secretion of a TNFR:Fc Fusion Protein following Pulmonary Administration of Pseudotyped Adeno-Associated Virus Vectors

Ziv Sandalon, Elizabeth Bruckheimer, Kurt Lustig et al. · Journal of Virology · 2004 · 34 citations · Full text

, , +14

Long-term Suppression of Experimental Arthritis Following Intramuscular Administration of a Pseudotyped AAV2/1-TNFR:Fc Vector

Ziv Sandalon, Elizabeth Bruckheimer, Kurt Lustig et al. · Molecular Therapy · 2007 · 20 citations · Full text

, , +14

Lassa antiviral LHF-535 protects guinea pigs from lethal challenge

Kathleen A. Cashman, Eric R. Wilkinson, Jeff Posakony et al. · Scientific Reports · 2022 · 15 citations · Full text

, , +13

1–5 of 5